Professor Jack Cuzick holds the distinguished position of John Snow Professor of Epidemiology at Queen Mary University of London where he serves as Director of the Wolfson Institute of Preventive Medicine and Head of the Centre for Cancer Prevention. His career has been defined by leadership at Barts and The London School of Medicine and Dentistry, establishing him as a global authority in cancer prevention research. With decades of expertise in epidemiological studies, he has pioneered methodologies that have transformed approaches to cancer risk assessment and prevention strategies worldwide. His academic journey has culminated in numerous leadership roles within major international research consortia focused on reducing cancer incidence through evidence-based interventions.
Professor Cuzick's groundbreaking work on breast cancer chemoprevention has reshaped clinical practice, with his influential 2006 publication laying foundational principles that continue to guide current prevention protocols. He conceived and led the landmark IBIS-II clinical trials which demonstrated the efficacy of anastrozole for breast cancer prevention in high-risk women, fundamentally altering international treatment guidelines. His innovative development of risk prediction models incorporating genetic, hormonal, and lifestyle factors has enabled personalized approaches to cancer prevention that benefit millions of women globally. His recent research on mammographic texture markers represents a significant advancement in early detection methods, further extending his profound impact on cancer prevention science.
As Director of the Centre for Cancer Prevention, Professor Cuzick has cultivated a world-class research environment that has trained generations of cancer prevention scientists who now lead programs worldwide. He currently oversees the IBIS-II-O observational study, ensuring long-term follow-up of trial participants to assess the enduring benefits and safety of preventive interventions. His expertise is consistently sought by major health organizations including the World Health Organization and National Institutes of Health to develop evidence-based cancer prevention guidelines. Professor Cuzick continues to drive innovation in cancer risk assessment through integration of genomic, imaging, and clinical data, focusing on refining personalized prevention approaches to further reduce cancer incidence globally.
